AFP and metabolic dysfunction-associated steatohepatitis: Although NAFLD/NASH was not a significant prognostic factor in that analysis for OS (HR 0.758, P = 0.092), the factors AFP (≥ 400 ng/mL) (HR 1.402, P = 0.009), BCLC C stage (HR 1.297, P = 0.035), later line introduction of lenvatinib (HR 0.737, P = 0.014), and mALBI grade 2b (HR 1.875, P < 0.001) were significant (Table 3b).